Related Experiment Video

Updated: Jun 4, 2025

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.2K

Therapeutic targeting of neuroinflammation in methamphetamine use disorder

Natasha Jeffery1, Phooi Yan Mock1, Kun Yang2

  • 1Centre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Future Medicinal Chemistry
|December 27, 2024
PubMed

Insights

This review explores targeting neuroinflammation to treat methamphetamine use disorders (MUDs). Focusing on targets like Toll-like receptor 4 (TLR4) and NLRP3 inflammasome may reduce METH-induced brain damage and improve outcomes.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Toxicology

Background:

  • Methamphetamine (METH) is a dangerous psychostimulant linked to high fatality rates.
  • METH use disorder (MUD) is associated with significant neuroinflammation and neurological damage.
  • Neuroinflammation contributes to cognitive impairment and neurodegeneration in MUD.

Purpose of the Study:

  • To review potential drug targets for neuroinflammation in MUDs.
  • To examine the role of Toll-like receptor 4 (TLR4) and NLRP3 inflammasome as therapeutic targets.
  • To assess the potential of targeting neuroinflammation for MUD treatment.

Main Methods:

  • Literature review of current research on METH, neuroinflammation, and therapeutic targets.
  • Analysis of studies focusing on TLR4 and NLRP3 inflammasome pathways.
  • Synthesis of findings on the impact of neuroinflammation on METH-induced neurological deficits.

Main Results:

  • Targeting neuroinflammation shows promise in mitigating METH-induced cognitive impairment and neurodegeneration.
  • TLR4 and NLRP3 inflammasome are key targets for managing METH-induced neuroinflammation.
  • Addressing neuroinflammation can potentially improve behavioral outcomes in MUDs.

Conclusions:

  • Targeting neuroinflammation represents a promising therapeutic strategy for MUDs.
  • Further research into combination therapies and novel drug delivery systems is warranted.
  • Developing neuroprotective agents is crucial for effective MUD interventions.
Keywords:
MethamphetamineNLRP3TLR-4neuroinflammationneurological disordersuse disorders

More Related Videos

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.1K
Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats09:43

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats

Published on: October 5, 2021

2.4K

Related Concept Videos

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
162
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
38
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
434